EOCN stock forecast, quote, news & analysis
Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas... Show more
Why Eocene Ltd. (EOCN) Stock Is Down 23% in the Last 30 Days
Key Takeaways
- EOCN shares have declined roughly 23% over the past 30 days, sliding from about $3.00 to $2.32 as of mid-November 2026.
- The move extends a longer downtrend, with the stock down roughly 49% over the last quarter.
- Eocene Ltd. (formerly Galmed Pharmaceuticals) completed its corporate rebranding and Nasdaq ticker change in September 2026 as part of a pivot toward a GI-focused medtech and biopharmaceutical platform.
- Pre-revenue status, a small market capitalization, and limited institutional ownership have kept investor sentiment cautious.
- The company regained Nasdaq minimum bid price compliance in early September 2026 after a period of depressed share prices.
- For additional detail, explore EOCN's Price Targets, Earnings, and Forecast.
- Explore Trending AI Robots for automated trading insights across thousands of tickers.
Eocene Ltd. (EOCN) Company Overview and Market Position
Eocene Ltd. is an Israel-based, GI-focused medtech and biopharmaceutical company headquartered in Ramat Gan. Formerly known as Galmed Pharmaceuticals Ltd., the company rebranded to Eocene Ltd. and changed its Nasdaq trading symbol from GLMD to EOCN effective September 10, 2026, to reflect a strategic shift from a clinical-stage biotech toward a diversified gastrointestinal platform.
The company's wholly owned subsidiary, Colospan Ltd., is a commercial-stage medical device developer focused on postoperative colorectal care. Its flagship product, CG-100, is an intraluminal bypass device designed to protect colorectal anastomoses and reduce the need for diverting stomas. CG-100 has received FDA Breakthrough Device Designation, is CE marked under the EU Medical Device Regulation, and is approved for investigational use in the U.S. under an FDA-approved IDE. Eocene's therapeutic portfolio also includes Aramchol, a synthetic fatty acid-bile acid conjugate being evaluated in liver disease and oncology indications.
Investors follow EOCN for its potential transition from a pre-revenue biotech into a platform with a nearer-term path to commercial device revenue in Europe and Israel, balanced against significant execution and funding risks.
Eocene Ltd. (EOCN) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, EOCN shares fell approximately 23%, from a closing price of about $3.00 in mid-October 2026 to $2.32 as of mid-November. The decline was punctuated by renewed selling pressure in early November, with the stock retreating from around $3.20 in late October toward the low-$2 range.
The pullback is part of a longer slide. Over the last quarter, the stock dropped roughly 49%, from about $4.56 in mid-August to current levels. Even after a brief rebound tied to the September rebranding, EOCN has traded below its 50-day and 200-day moving averages, reflecting persistent downside momentum in a thinly traded, micro-cap name.
What Drove EOCN Stock Price in the Last 30 Days
The recent decline reflects a combination of company-specific and market-structure factors rather than a single catalyst. Eocene remains pre-revenue, and its $11.4 million cash position as of June 30, 2026 underscores a limited runway as it funds the clinical and commercial development of CG-100 and Aramchol.
Dilution concerns have weighed on sentiment. The company's share count rose more than 200% year over year, and it terminated its Standby Equity Purchase Agreement (SEPA) with Yorkville in September 2026 after raising roughly $7.3 million through the facility. With a market capitalization of only a few million dollars, low institutional ownership, and modest daily volume, EOCN is susceptible to outsized price swings on limited trading activity, which has amplified the downward drift over the past month.
What Drove EOCN Stock Performance Over the Last Quarter
The broader multi-month decline reflects a transitional period for the company. After regaining Nasdaq minimum bid price compliance in early September 2026, Eocene executed its rebranding and symbol change, but the initial enthusiasm faded as investors reassessed the company's near-term revenue trajectory and financing needs.
The stock remains far below its 52-week highs, with the 52-week price change down more than 70%. While the Colospan acquisition introduced a potential path to commercial device revenue in Europe and Israel, CG-100 is not yet approved for commercial use in the U.S., and the company must still fund ongoing development. These realities have kept the quarterly trend firmly negative despite the strategic repositioning.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots from a marketplace of hundreds of automated strategies that trade across thousands of tickers. Only the top-performing and most relevant bots appear in this section, helping traders filter through a broad universe of signal-based systems. The bots vary by strategy, holding timeframe, and performance metrics, so users can compare approaches that range from short-term technical setups to longer-horizon patterns. For investors monitoring volatile micro-cap names like EOCN, the page offers a way to explore systematic, data-driven trading ideas alongside traditional research.
EOCN Stock Forecast Drivers: What Investors Should Watch Next
Several factors could shape EOCN's direction in the months ahead. The company's next quarterly earnings report is estimated for late November 2026, and investors will likely scrutinize its cash position, operating expenses, and any updates on CG-100's commercialization in Europe and Israel as well as its U.S. regulatory pathway. Progress on Aramchol clinical programs and any new financing, licensing, or partnership activity will also be key. Broader risks include continued dilution, execution challenges tied to the medtech pivot, and the inherent volatility of a low-float, pre-revenue micro-cap. Market participants should monitor these developments closely while recognizing the elevated risk profile.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
EOCN sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for EOCN moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EOCN as a result. In 87 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EOCN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for EOCN entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where EOCN advanced for three days, in 182 of 213 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
EOCN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.124) is normal, around the industry mean (3.498). P/E Ratio (-0.756) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. EOCN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EOCN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry Biotechnology